top of page

Apellis Pharmaceuticals (APLS)

BIOPHARMA STOCK NEWS FLASH

APLS provides SYFOVRE safety update


Background:

SYFOVRE approved by FDA

• Feb 2023

• pegcetacoplan injection

• for GA 2nd to AMD


July 17, 2023

News breaks re: safety concerns

Stock down >50%

Today’s Safety Update

• 7 confirmed retinal vasculitis since launch

⇨ 4 occlusive

⇨ 3 non-occlusive

⇨ +1 unconfirmed

2 in April

2 in May

3 in June


• 68,000 commercials vials distributed

• Updated analysis

⇨ No mfg issues

⇨ No quality issues

⇨ No contaminants

• 23,000 clin trial injections

⇨ Deeper scrub of data

⇨ No vasculitis

More ahead for APLS this weekend/week

7/31 Q2 update

#ASRS2023 presentations

APLS @ #ASRS23 7/28-8/1

• 7 presentation in coming days at #ASRS23

⇨ Tomorrow - 30 month safety & efficacy

ASRS Safety committee (ReST)

Reported safety update today*


• ReST Committee working with APLS

• Similar info reported today as APLS update

• But some info on …

⇨ Panuveitis & Infectious endophthalmitis

⇨ Positive Committee comments re: APLS interactions

Prior report on Internet...

Undisclosed conflict on ReST committee*

*From info on Internet not confirmed by BPIQ


EcoR1 loads up on APLS

after recent stock drop

APLS is a hedge fund favorite

• 10/36 top biopharma funds

⇨ end Q1 filings

• 1 of most widely held smid-caps


Wall Street analysts re: APLS safety issue ...

• Speculate solvable

⇨ Not MOA

⇨ See images




Back to biopharma hedge funds

Since safety issues surfaced ...

From SEC filings ...

No reported selling

In fact...

7/18/23

EcoR1 bought more APLS

• 855,900 shares

• Now owns 6,307,547

In a few weeks ...

• Hedge fund Q2 13F filings

• Value of APLS holdings prob <1/2 Q1

⇨ because stock price drop

⇨ Not because HFs selling

⇨ HFs holding APLS


Article History:

Originally posted 7/31/23 (RB)


This is not investment, legal or tax advice. Do your own diligence and seek the advice of professionals.


0 comments

Comentarios


bottom of page